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Abstract
Object: Antiangiogenic treatments are beginning to give promising outcomes in many vascular diseases including tumor
angiogenesis. In this current study the antiangiogenic and pro-apoptotic actions of a1(IV)NC1 and its N- and C- peptides
a1S1(IV)NC1, a1S2(IV)NC1 were investigated in-vitro and in-vivo.
Study Method: Endothelial cells (ECs) were treated with a1(IV)NC1, a1S1(IV)NC1, a1S2(IV)NC1 and in-vitro proliferation,
migration, tube formation and apoptotic assays were executed. FasL, Fas, Caspase-8, -3 and PARP activations were studied
using immunoblotting analysis using specific antibodies. Also the in-vivo antiangiogenic and pro-apoptotic effects were
tested using a1(IV)NC1 in a mice model.
Results: Like a1(IV)NC1, its N- and C- terminal a1S2(IV)NC1 and a1S1(IV)NC1 domains posses anti-proliferative, pro-
apoptotic activity and inhibit ECs migration and tube formation in-vitro. Both a1S1(IV)NC1 and a1S2(IV)NC1 domains
promote apoptosis by activating FasL and down stream apoptotic events including activation of caspase-8, -3 and PARP
cleavage in a dose dependent manner in-vitro in ECs. Tumors in mice showed apoptotic TUNEL positive microvasculature
upon a1(IV)NC1 treatment, indicating inhibition of tumor angiogenesis and tumor growth. Further, the antitumor activity of
a1(IV)NC1 was abrogated when caspase-3 inhibitor was used. These results conform additional properties of a1(IV)NC1 as
an endogenous angioinhibitor that induces apoptosis in-vitro and in-vivo by activating FasL mediated caspase-3.
Significance: a1(IV)NC1 and its N- and C- terminal a1S1(IV)NC1 and a1S2(IV)NC1 domains also posses pro-apoptotic and
angioinhibitory activity in-vitro and in-vivo. a1(IV)NC1 regulates tumor angiogenesis by activating FasL mediated apoptosis
in-vitro and in-vivo. These results demonstrate that a1(IV)NC1 and its peptides inhibit neo-vascular diseases.
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Introduction
Angiogenesis, the formation of new blood vessels from
preexisting blood vessels, is a very stringently controlled program
and normally does not occur, except during development and
wound repair processes [1,2]. This stringent regulation of
angiogenesis is manifested by a balance between pro-and anti-
angiogenic factors, which keep angiogenesis in check [2].
However, the dynamic equilibrium between pro-angiogenic and
anti-angiogenic factors are controlled under many pathological
settings, including tumor angiogenesis in cancer progression and
other incidents like as age-related macular degeneration, retinop-
athy of prematurity and diabetic retinopathy resulting in the
growth of abnormal new blood vessels [3–5].
Vascular basement membranes (VBM) constitute an important
component of blood vessels [6]. Makeover of VBM can provide
vital pro- and anti-angiogenic molecules to control formation of
new blood vessels [7–9]. Type IV collagen is a major component
of VBM and plays a critical role in new blood vessel development
[6]. Proteolytic degradation of type IV collagen in the VBM
generates numerous antiangiogenic molecules [7,10–12]. One
such antiangiogenic molecule derived from type IV collagen non-
collagenous (NC1) domain a1 chain, a1(IV)NC1, has been tested
in variety of tumor angiogenesis studies in mice [13–15]. However,
the molecular and cellular mechanism(s) responsible for inhibition
of angiogenesis is not yet clearly understood. The in-vitro and in-vivo
studies have demonstrated that a1(IV)NC1 can directly affect
endothelial cell migration and impact their proliferation and
sprouting [14]. Earlier we have demonstrated that a1(IV)NC1
promotes apoptosis via activation of caspase-3 and PARP cleavage
by inhibiting FAK/p38-MAPK/Bcl-2 and Bcl-xL signaling
cascade [15]. These results provide a clear understanding about
the apoptotic signaling and therapeutic potential of a1(IV)NC1
molecule in neovascular diseases. However, the effects of
a1(IV)NC1 and its N- and C-terminal domains a1S1(IV)NC1
and a1S2(IV)NC1 on endothelial cell apoptosis and neo-vascu-
larization have not been previously studied.
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In the present study, we demonstrate that a1(IV)NC1 and its N-
and C-terminal domains a1S1(IV)NC1 and a1S2(IV)NC1 are
potent inhibitors of endothelial cell proliferation, migration and
tube formation in-vitro and tumor angiogenesis in-vivo. a1(IV)NC1
promotes apoptosis via activation of caspase-3 and PARP
cleavage, presumably by inhibiting FAK/p38-MAPK/Bcl-2 and
Bcl-xL signaling cascade [15]. Here in this study, we show that N-
and C-terminal domains of a1(IV)NC1 cross talk with FasL and
activate FasL and its downstream apoptotic missionary including
caspase-8, caspase-3 and PARP cleavage in-vitro. Furthermore, we
identified that a1(IV)NC1 promotes apoptosis in tumor vascula-
ture and inhibits angiogenesis and this effect was reversed by a
caspase-3 specific inhibitor DEVD in-vivo. These findings contrib-
ute significantly towards understanding the apoptotic activation in
proliferating ECs and therapeutic potential of endogenous
angioinhibitor a1(IV)NC1 and its N- and C-terminal
a1S1(IV)NC1 and a1S2(IV)NC1 domains in tumor growth and
tumor angiogenesis.
Materials and Methods
Fetal calf serum (FCS), Endothelial basal medium (EBM-2) and
Endothelial cell growth medium (EGM-2) were obtained from
Fischer Scientific Inc. Penicillin and streptomycin and low melting
agarose were purchased from Sigma-Aldrich and cell stains
hematoxylin and eosin (H&E) were purchased from Fischer
Scientific Inc. SephadexTM-G 100, -G 25 and -G 200 were
purchased from GE Healthcare Bio-Sciences AB. BD MatrigelTM
Matrix (14.6 mg/ml) was purchased from BD Biosciences
Discovery Laboratory. T4-DNA ligase (bacteriophage ligase),
different restriction enzymes and polymerases were purchased
from New England Biolabs. SCC-PSA1 tumor cells were
purchased from ATCC. Caspase inhibitors z-DEVD-fmk was
from Enzyme System Products. H&E staining kit form Fisher
Scientific Inc. CD31 antibody was purchased from Upstate.
Caspase-3, -8, PARP, FasL and Fas antibodies were purchased
from Cell Signaling. MTT assay kit was purchased from
Chemicon.
Ethics Statement. Boys Town National Research Hospital
IACUC committee approved all mice studies.
Tissue culture procedure
SCC-PSA1 cells were maintained in 10% FCS with penicillin/
streptomycin (100units/ml each) and maintained at 37uC incuba-
tor with 5% CO2. Primary mouse choroidal endothelial cells (EC)
were maintained as describe previously [16,17]. EC were
maintained in 40% HAM’s F-12, 40% DME-Low Glucose, 20%
FCS supplemented with heparin (50 mg/L), endothelial mitogen
(50 mg/L), L-glutamine (2.0 mM), penicillin/streptomycin
(100units/ml each), Na Pyruvate (2.5 mM), NEAA (1X), 5.0 mg/
L of murine INF-c and cultured on 0.8% gelatin coated plates at
33uC with 5% CO2.
Cloning, Expression and Purification of a1(IV)NC1 and its
N- and C- terminal domains a1S1(IV)NC1 and
a1S2(IV)NC1
The coding sequence corresponding to the N- and C-terminal
non-collagenous domains (NC1) from human Collagen type IV a1
chain was isolated from the placental cDNA using one-step reverse
transcriptase-PCR (RT-PCR) (Invitrogen, CA). The N- terminal
subunit 330-bp from full length a1(IV)NC1 was amplified using
the forward primer: ATACATATGGGCTTCCTTGTGAC-
CAGGCATA and the reverse primer: CACAAGCT-
TAGGCGCCTCACACACAGCAC and cloned between ‘NdeI’
and ‘XhoI’ sites of pET22b. The C- terminal subunit 330-bp from
full length a1(IV)NC1 was amplified using the forward primers:
GTGCATATGGTGCACAGCCAGACCAT and the reverse
primer: GTGGCAGCAGCCAACTCA and cloned between
‘NdeI’ and ‘XhoI’ sites of pET22b. Amplification and cloning
was carryout similarly as reported in our earlier publication [18].
The positive clone was used to transform E. coli strain BL21 for
protein expression and purification was performed similarly as
reported earlier [18].
Purification of a1(IV)NC1 and a1S1(IV)NC1 and
a1S2(IV)NC1 domains
Inclusion bodies of a1(IV)NC1, a1S1(IV)NC1 and
a1S2(IV)NC1 were prepared with minor modifications as reported
[18]. In addition to the renaturation by stirring method, on-
column renaturation was performed for simultaneous renaturation
and purification of the a1(IV)NC1, a1S1(IV)NC1 and
a1S2(IV)NC1 domains. Denatured a1(IV)NC1, a1S1(IV)NC1
and a1S2(IV)NC1 protein in 800 ml aliquots was loaded onto the
Sephadex G-100, Superdex-200 followed by Sephadex G-25
columns similarly as reported [18]. The fractions containing
a1(IV)NC1, a1S1(IV)NC1 and a1S2(IV)NC1 were pooled and
further concentrated by lyophilization as reported. Endotoxin
levels in the final purified a1(IV)NC1, a1S1(IV)NC1 and
a1S2(IV)NC1 domains samples were estimated using the Limulus
Amebocyte Lysate (LAL) QCL-1000 assay kit (Lonza) according to
the manufacturer instructions and also similarly reported in earlier
publication [18].
Proliferation assay
A suspension of 7000-cells/well mouse choroidal endothelial
cells (ECs) in a 96 well plate was used in proliferation assay. Cells
were grown in 96 well plate under 0.5% FBS supplemented with
heparin, endothelial mitogen, glutamine and penicillin/strepto-
mycin. After 24-hrs, medium was replaced with ECs medium
containing 10% FCS and different concentrations of a1(IV)NC1
or its N- and C-terminal a1S1(IV)NC1 and a1S2(IV)NC1
domains (0.25 and 2.0 mM) and after 48-hrs relative levels of
methylene blue incorporation was measured as reported [14,17].
Migration assay
About 1.06104 cells/well of ECs were seeded in serum free
medium with and without recombinant a1S1(IV)NC1 and
a1S2(IV)NC1 (1.0 mM). Medium containing 10 gg/ml of VEGF
was placed into the bottom wells of the Boyden chamber and
incubated for about 48-hrs at 37uC with 5% CO2. The numbers of
ECs that were migrated and attached to the bottom side of the
Boyden chamber membrane were counted as reported earlier
[14,19].
Tube formation assay
Briefly, Matrigel matrix about 250 ml was thawed overnight on
ice-cold room and added to each well of a 24-well plate and
allowed to solidify for 30-min at 37uC culture incubator. A
suspension of about 506103 ECs in medium without antibiotic
was plated on top of the Matrigel matrix. The ECs were than
incubated with and without a1(IV)NC1 or its N- and C-terminal
a1S1(IV)NC1 and a1S2(IV)NC1 domains (1.0 mM) for 48-hrs at
37uC and viewed using a CK2 Olympus microscope [14,20,21].
Cell viability assay
Endothelial cell viability was assessed by MTT assay [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazoliumbromide] following
FasL Mediated EC Apoptosis by a1(IV)NC1 Peptides
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the manufacturer’s protocol instructions. About 7.06103 EC cells/
well were plated on a 96-well plate, over night serum starved and
stimulated with 10% FCS containing medium. After 24-hrs
different concentration of a1(IV)NC1 or its N- and C-terminal
a1S1(IV)NC1 and a1S2(IV)NC1 domains (0.25–2.0 mM) were
added and incubated for 48-hrs. Apoptosis was monitored by
trypan blue exclusion using the cell death detection ELISA kit
[22].
FasL and caspase activation assay
About 1.06106 serum starved EC were collected and suspended
in serum free medium. These ECs were pretreated with
a1(IV)NC1 N- and C-terminal a1S1(IV)NC1 and a1S2(IV)NC1
domains (1.0 mM) and incubated on 10-cm2 dishes for 6 and 18-
hrs. After 6 and 18-hrs, the floating ECs were collected, adherent
cells washed once with cold PBS. Adhering and floating cells were
lysed on ice in RIPA lysis buffer and centrifuged at 4uC for 30-min
at 13000-rpm. About 30 mg of cytosolic extract/lane was
separated using 10% SDS-PAGE followed by immunoblotting
with anti-FasL, Fas, caspase-8, caspase-3 and PARP antibodies.
Immunoreactivity of FasL, Fas, cleaved caspase-8, caspase-3 and
PARP proteins were visualized using ECL detection kit as reported
[15].
In-vivo tumor studies
About 1.06106 SCC-PSA1 teratocarcinoma tumor cells were
implanted subcutaneously into each mouse at dorso-lateral sides.
Six male 129/Sv mice were used in each treatment and control
groups. Once the tumors reached around 100-mm3 sizes, 30 mg of
a1(IV)NC1 or in combination with 10 mg of caspase-3 specific
inhibitor DEVD in 100 ml total volume was intravenously injected
to each mouse daily for 15-days. All the experimental mice were
scarified and tumors and other organs were collected [21,31].
Immunohistochemical staining
Tumors from control and a1(IV)NC1 or in combination with
DEVD treated mice were embedded in OTC compound and
snap-frozen in liquid nitrogen. Tumor sections were incubated for
2-hrs with 5% BSA in PBS to block any nonspecific binding and
then incubated with anti-CD-31 antibody for 1-hr followed by
incubation with peroxidase-labeled goat anti-rabbit secondary
antibody at 37uC. The number of CD-31 positive blood vessels per
10-microscopic fields from four tumor sections per condition was
counted [14,23].
TUNEL assay for apoptosis
To evaluate the relative levels of CD-31 positive vascular or
cellular apoptosis, and to quantify cellular apoptosis in tumors
from control and a1(IV)NC1 or in combination with DEVD
treated mice with and without a1(IV)NC1 treatment, we used
ApopTag apoptosis detection kit. Briefly the tumor sections were
incubated with 5% BSA in PBS to block any nonspecific binding
and stained with ApopTag apoptosis detection reagents following
the manufacturer’s instructions. To determine whether CD-31
positive blood vessels were undergoing apoptosis, control and
a1(IV)NC1 or in combination with DEVD treated tumor sections
were co-incubated with both ApopTag reagents and anti-CD-31
antibody. Tumor sections were washed twice and incubated with
rhodamine-conjugated goat anti-rabbit secondary antibody for 1-
hr at 37uC. The fluorescence staining was analyzed using a
fluorescence microscope [14,23].
Results
Distinct anti-angiogenic activities of a1(IV)NC1 and its N-
and C- terminal domains a1S1(IV)NC1 and a1S2(IV)NC1
a1(IV)NC1 is an endogenous metabolite generated from the
non-collagenous (NC1) domain of a1 chain of type IV collagen by
matrix metalloproteinases-9 (MMP-9) [24,25]. It was discovered as
an angioinhibitory protein with substantial anti-tumor activities
[13,14]. The present study was aimed at understanding the
molecular mechanism(s) underlying angioinhibition by a1(IV)NC1
and its N- and C- terminal a1S1(IV)NC1, a1S2(IV)NC1 domains
and its implications in prevention of tumor angiogenesis. Our
studies tried to identify the angioinhibitory and pro-apoptotic
activities of a1(IV)NC1 and its N- and C- terminal a1S1(IV)NC1,
a1S2(IV)NC1 domains in mouse choroidal endothelial cells (ECs).
We have performed different angiogenesis experiments to
determine the angioinhibitory potential of a1(IV)NC1 and its N-
and C-terminal domains a1S1(IV)NC1 and a1S2(IV)NC1 using
ECs. Many serum proteins are major pro-angiopromoting factors,
elevated levels or imbalance of serum proteins (example VEGF
and bFGF) are responsible for the majority of ocular angiogenesis
driven by ischemia and also tumor angiogenesis. We first
determined serum stimulated angioinhibitory activity of
a1(IV)NC1 and its N- and C-terminal domains a1S1(IV)NC1
and a1S2(IV)NC1 by measuring ECs proliferation. The anti-
proliferative effect of a1(IV)NC1 and its N- and C-terminal
domains were tested in ECs using methylene blue incorporation.
Fetal calf serum (10% FCS) stimulated proliferation of ECs were
significantly inhibited by a1(IV)NC1 its N-and C-terminal
a1S1(IV)NC1 and a1S2(IV)NC1 domains in a dose dependent
manner (Figure 1A). Interestingly, both N- and C-terminal
a1S1(IV)NC1 and a1S2(IV)NC1 domains were showing similar
proliferation inhibitory activity when compared to its parent
molecule a1(IV)NC1.
Migration of endothelial cells is basically essential during neo-
vascularization [14,26]. Migration of ECs across a PVD mem-
brane towards VEGF in a Boyden chamber was inhibited by
1.0 mM N-and C-terminal a1S1(IV)NC1 and a1S2(IV)NC1
domains (Figure 1B). We additionally confirmed the angioinhi-
bitory action of a1(IV)NC1 and its two domains a1S1(IV)NC1
and a1S2(IV)NC1 by a functional assay of ECs tube formation
[20]. Tube formation on Matrigel is associated with ECs
proliferation, migration and survival [1]. Treatment of ECs with
a1(IV)NC1 and its domains a1S1(IV)NC1 and a1S2(IV)NC1
inhibited tube formation equally on Matrigel matrix (Figure 1C).
Our previous study reported that the angioinhibitory activity of
a1(IV)NC1 is mediated through a1b1 integrin [14,21]. Surpris-
ingly, in this study we noticed that ECs when treated with N- and
C-terminal domains and full length a1(IV)NC1 (1.0 mM) were
appeared rounded (apoptosis-like) and some of the cells detach
from the Matrigel matrix (data not shown). This might be due
to activation caspases and apoptosis in ECs treated with
a1(IV)NC1 or its N- and C- terminal domains a1S1(IV)NC1
and a1S2(IV)NC1 similarly as reported earlier [15].
Further we also tested the angioinhibitory activity at different
doses of a1(IV)NC1 and its N-and C- terminal domains
a1S1(IV)NC1 and a1S2(IV)NC1 (0, 0.25, 0.5, 1.0, 1.5, 2.0 mM)
by MTT cell viability assay after 10% FCS stimulation in ECs.
The results reveal that ECs proliferation was significantly
increased by FCS stimulation which was inhibited by a1(IV)NC1
and its N- and C-terminal domains dose dependently after 24-hrs
(Figure 2).
FasL Mediated EC Apoptosis by a1(IV)NC1 Peptides
PLOS ONE | www.plosone.org 3 December 2013 | Volume 8 | Issue 12 | e80555
FasL mediated in-vitro apoptotic activity of a1(IV)NC1
and its N- and C- terminal a1S1(IV)NC1 and a1S2(IV)NC1
domains
Caspase-3 is a pivotal molecule mediating cellular apoptosis
[27]. Earlier we demonstrated that a1(IV)NC1 induces apoptosis
in endothelial cells by activating Caspase-3 [15]. Here in this
study, we tested, whether a1(IV)NC1 and its N- and C-terminal
domains posses pro-apoptotic activity or not? Interestingly, ECs
incubated with a1(IV)NC1 and its N- and C- terminal domains
showed dose and time dependent activation of FasL without
affecting Fas expression compared to control untreated cells
(Figure 3A & B). These results suggest both a1S1(IV)NC1 and
a1S2(IV)NC1 domains may cross talk with death receptor,
activating FasL mediated apoptosis in ECs. These results
demonstrate that a1(IV)NC1 and its two domains a1S1(IV)NC1
and a1S2(IV)NC1 promoted apoptosis through FasL in addition
to MAPK signaling inhibition [15].
We further assessed whether a1S1(IV)NC1 and a1S2(IV)NC1
induces activation of FasL downstream different caspases such as
caspase-8 and caspase-3. We treated ECs with a1S1(IV)NC1 and
a1S2(IV)NC1 and observed that activation of caspase-8
(Figure 4A and B). These results demonstrate that full length
a1(IV)NC1, both its N- and C- terminal domains a1S1(IV)NC1
and a1S2(IV)NC1 induced cellular apoptosis by activating FasL
and activating downstream caspase-8. Among the known caspases,
caspase-3 is an important effector molecule for most cellular
apoptosis [27]. To study whether caspase-3 could be activated by
a1S1(IV)NC1 and a1S2(IV)NC1 domains, we treated ECs with
different doses of a1S1(IV)NC1 and a1S2(IV)NC1 and observed
activation of caspase-3 in a time dependent manner (Figure 4C
and D). Here, we also identified that activation PARP cleavage
which is further down stream to FasL, caspase-8 and caspase-3 in
Figure 1. Proliferation (A). Graph summarizes relative levels of methylene blue incorporation in mouse choroidal endothelial cells (ECs) treating
with different concentrations of a1(IV)NC1 and its N- and C terminal a1S1(IV)NC1 and a1S2(IV)NC1 domains compared with and without FCS controls
after 48-hrs. All groups represent triplicate samples and data in the graphs are represented as mean6SD. Migration (B). Number of ECs with and
without a1S1(IV)NC1 and a1S2(IV)NC1 domains migrated towards VEGF on the underside of Boyden chamber membrane were shown and cells
viewed using a light microscope after 48-hrs representative fields (1006magnification) shown. Tube formation (C). ECs were plated on Matrigel
coated plates in endothelial cell medium as control or with 1.0 mM a1(IV)NC1, a1S1(IV)NC1 and a1S2(IV)NC1 proteins. Tube formation was assessed
using a light microscope after 48-hrs, and representative fields at 1006magnification were shown.
doi:10.1371/journal.pone.0080555.g001
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ECs treated with a1S1(IV)NC1 and a1S2(IV)NC1 time and dose
dependently (Figure 5A and B). These results demonstrate that
activation of ECs apoptosis by a1S1(IV)NC1 and a1S2(IV)NC1
domains by activating FasL and its down stream caspases and
PARP cleavage.
Neutralizing anti-tumorigenic activity of a1(IV)NC1 by
caspase-3 inhibitor
To further conform the pro-apoptotic activity of a1(IV)NC1
also partly regulated by caspase-3 activation and apoptosis, we
carried in-vitro tumor studies with a1(IV)NC1, or a1(IV)NC1 co-
administrated with caspase-3 inhibitor DEVD to tumor bearing
mice. Consistent to our earlier findings, administration of
a1(IV)NC1 significantly inhibited SCC-PSA1 tumor growth and
tumor angiogenesis in-vivo [27]. In contrast, treatment with
caspase-3 specific inhibitor DEVD alone showed significant effect
on inhibition of tumor growth. The antitumor activity of
a1(IV)NC1 was significantly attenuated when a1(IV)NC1 and
DEVD were co-administrated to tumor bearing mice (data not
shown).
To assess the antitumor effects of a1(IV)NC1 and its ability to
activate microvasculature apoptosis, control and a1(IV)NC1
treated mice tumor sections were stained with anti-CD31 antibody
(Fig. 6, middle panel). In control tumors, less TUNEL positive
apoptotic staining was detected whereas elevated levels of
apoptosis was observed in tumors that were treated with
a1(IV)NC1 (Fig. 6). DEVD treatment alone meagerly affected
overall tumor cell apoptosis when compared with a1(IV)NC1.
Further, a significant number of ECs in tumor vasculature
underwent apoptosis upon a1(IV)NC1 treatment when compared
to control tumors, as observed through CD31/TUNEL dual
staining (Fig. 6, right panel yellow). Interestingly, co-admin-
istration of a1(IV)NC1 with DEVD to tumor bearing mice
significantly reduced EC apoptosis in microvasculature that was
induced by a1(IV)NC1. Further apoptotic tumor cells were
observed in a1(IV)NC1 treated tumors using TUNEL staining.
This could be the result of an indirect effect since the
microvasculature is affected by a1(IV)NC1 treatment, and the
tumor cells possibly suffer from oxygen supply and nourishment
resulting in apoptosis. This effect was observed at elevated levels in
cells undergoing apoptosis, other than CD-31 positive ECs (Fig. 6,
left and right panels). We also quantified the microvascular
density and number of apoptotic vessels through TUNEL staining
and by counting the number of CD-31 positive blood vessels (data
not shown). Collectively, our results demonstrate that a1(IV)NC1
and its -N and -C terminal domains induced activation of FasL
mediated caspase-3 activation and apoptosis in proliferating
endothelial cells.
Figure 2. Cell viability. MTT assay was performed to evaluate mouse choroidal endothelial cells (ECs) viability after treatment with different
concentrations of a1(IV)NC1 and its N- and C- terminal domains a1S1(IV)NC1 and a1S2(IV)NC1. ECs grown with and without FCS as positive and
negative controls. Experiments were performed with three replicates and data in the graphs are represented as mean6SD.
doi:10.1371/journal.pone.0080555.g002
Figure 3. FasL activation (A and B). Mouse choroidal endothelial
cells were incubated with and without different doses of a1S1(IV)NC1
and a1S2(IV)NC1 domains for 6 and 18-hrs, and total cells were
collected, lysed for 30-min in ice-cold RIPA lysis buffer and about 25 mg
of total cytosolic extract per lane was separated and immunoblotted
with primary antibodies against FasL and Fas. In panel A and B, b-
catenin was shown as loading control.
doi:10.1371/journal.pone.0080555.g003
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Discussion
Many endogenous metabolites generated from type IV collagen
were identified as pro-apoptotic, antiangiogenic and anti-tumor-
igenic in nature [12–15,21,25,28–32]. The non-collagenous (NC1)
domain released by proteolytic activity from type IV collagen a1
chain (a1(IV)NC1) was identified as an antiangiogenic molecule,
where as its N- and C terminal domains apoptotic activity is not
yet studied. Antiangiogenic activity of a1(IV)NC1 is mediating
through a1b1 integrin [14,21]. However, it is critical to examine
a1(IV)NC1 and its both its N- and C- terminal domains
a1S1(IV)NC1 and a1S2(IV)NC1 effects in several well defined
relevant in-vitro experiments before confirming that these domains
are also antiangiogenic. In this study, we tested the antiangio-
genic/pro-apoptotic effects of a1(IV)NC1 and its N- and C-
terminal domains in different in-vitro and in-vivo experiments.
We demonstrate in this study for the first time, that a1(IV)NC1
and its N- and C- terminal domains inhibits serum induced EC
proliferation, migration and tube formation. In addition, we also
identified that both a1S1(IV)NC1 and a1S2(IV)NC1 domains
activates caspase-8, caspase-3/PARP cleavage through FasL
activation in proliferating endothelial cells. This is coherent with
the earlier studies revealing that antiangiogenic activity of
a1(IV)NC1 is mediated through a1b1 integrin signaling and
apoptosis [14,33]. a1(IV)NC1 and its N- and C- terminal
a1S1(IV)NC1 and a1S2(IV)NC1 domains activated FasL medi-
ated apoptosis in ECs. Understanding the mechanism(s) of action
of a1S1(IV)NC1 and a1S2(IV)NC domains is crucial for their
therapeutic development and use. Thus, a1(IV)NC1 and its N-
Figure 4. Caspase-8 activation (A and B). Mouse choroidal
endothelial cells (ECs) were incubated with and without different doses
of a1S1(IV)NC1 and a1S2(IV)NC1 domains for 6 and 18-hrs, and total
cells lysed for 30-min in ice-cold RIPA lysis buffer and about 25 mg of
cytosolic extract per lane was separated and immunoblotted with
primary antibodies against caspase-8. Caspase-3 activation (C and
D). ECs were incubated with and without different doses of
a1S1(IV)NC1 and a1S2(IV)NC1 domains and total cytosolic extract
immunoblotted with primary antibodies against caspase-3.
doi:10.1371/journal.pone.0080555.g004
Figure 5. PARP activation (A and B). Mouse choroidal endothelial
cells (ECs) were incubated with and without different doses of
a1S1(IV)NC1 and a1S2(IV)NC1 domains for 6 and 18-hrs, and total cells
lysed for 30-min in ice-cold RIPA lysis buffer and about 25 mg of
cytosolic extract per lane was separated and immunoblotted with
primary antibodies against PARP.
doi:10.1371/journal.pone.0080555.g005
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and C- terminal domains promotes apoptosis in proliferating ECs
and inhibits tumor angiogenesis, these endogenous molecules may
be an effective therapeutic candidate for treatment of many
neovascular diseases. Further evaluation through extensive labo-
ratory studies on these molecules is needed to address the function
of these angioinhibitors to be considered for the clinical trials.
Earlier lessons from preclinical trials of angiostatin, endostatin,
Thrombospondin-1 (ABT-510) and 2-ME suggest that more basic
laboratory studies are required to better understand the mecha-
nism of actions associated with these angioinhibitor molecules.
Presently, some of the angioinhibitory agents such as Bevacizumab
and VEGFR tyrosine kinase inhibitors; Vatalanib (PTK787/ZK
222584), Semaxanib (SU5416), Sunitinib (SU11248), Sorafenib
(BAY 43-9006) are in clinical trials [34,35]. Many other
angioinhibitory drugs [Macugen (pegaptanib sodium), Lucentis
(formerly RhuFab V2), tryptophanyl-tRNA synthetase (TrpRS),
VEGF-TRAP, AdPEDF, AG-013958, Avastin (bevacizumab),
JSM6427 etc] inhibit ocular neovascularization and prevent
leakiness of retinal blood vessels by preventing binding of VEGF
to its receptors on endothelial cells [15,36–42]. Endogenous
metabolite, a2(IV)NC1/a3(IV)NC1 were also reported to laser
induced CNV by promoting apoptosis of endothelial cells in-vivo
[10].
Our findings suggest that a1(IV)NC1 and its N- and C- terminal
domains a1S1(IV)NC1 and a1S2(IV)NC1 may also be effective in
inhibition of tumor angiogenesis by activating caspase-3 in new
blood vessels. This is further supported by earlier findings that
another angioinhibitor, a3(IV)NC1 regulate angiogenesis in a
number of in-vitro and in-vivo models [10]. Regression of tumor
growth in mice upon a1(IV)NC1 treatment is associated with
reduced tumor vasculature and increased TUNEL positive
endothelial and tumor cells when compared to control tumors,
indicating in-vitro activation of caspase-3. This suggests that
a1(IV)NC1 activates caspase-3 and inhibits tumor angiogenesis
and tumor growth. Thus, this work not only supports our efforts in
development of a1(IV)NC1, its N- and C- terminal domains
a1S1(IV)NC1 and a1S2(IV)NC as a potential candidate for tumor
angiogenesis neovascular diseases.
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